WithdrawnNot Applicable

Biomarker for Pompe Disease (BioPompe)

Stopped: Transition into BioMetabol

Germany, India, Sri Lanka0Started 2018-08-20

Plain-language summary

Development of a new MS-based biomarker for the early and sensitive diagnosis of Pompe disease from blood (plasma)

Who can participate

Age range12 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Informed consent will be obtained from the patient or the parents before any study related procedures. * Patients older than 12 months * The patient has a diagnosis of Pompe disease Exclusion Criteria: * No Informed consent from the patient or the parents before any study related procedures * Patients younger than 12 months * The patient has no diagnosis of Pompe disease

What they're measuring

Development of a new MS-based biomarker for the early and sensitive diagnosis of Pompe disease from plasma

Timeframe: 24 month

Trial details

NCT IDNCT01457443

SponsorCENTOGENE GmbH Rostock

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2021-12-31

View on ClinicalTrials.gov More Cardiac Diseases trials